Cardio Catch-Up: Boston Scientific Pushes US TAVR Timeline Again
Executive Summary
Boston Scientific's plan to launch the Acurate neo2 TAVR system in the US this year depended on earning an FDA approval based on interim results from the ACURATE IDE trial. The company is optimistic the full data set will support approval after they are announced later this year.